Aclaris Therapeutics, Inc. (ACRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.17+3.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACRS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain sufficient cash, cash equivalents, and marketable securities to fund operations through 2028 without additional financing.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities increased from $151.4 million at 2025-Q4 to $170.6 million at 2026-Q2. Management has consistently affirmed sufficient liquidity to fund operations through the end of 2028, and the trajectory shows stable to improving cash resources, delivering on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2028.”
“The Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2028.”
“The Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2028”
Complete Phase 1b proof-of-concept trials in asthma and atopic dermatitis and initiate Phase 2b trials in asthma and AD in late 2026.
Stated as a priority in 3 of last 3 quarters. Management has consistently communicated ongoing Phase 1b POC trials in asthma and AD with top line results expected in H2 2026 and plans to initiate Phase 2b trials in asthma and AD in Q4 2026. The clinical development program is progressing on schedule, delivering on stated milestones.
“Timelines reaffirmed for upcoming top line results from Phase 1b POC trials of ATI-052 in asthma and AD; confirmed intent to initiate Phase 2b program in Q4 2026.”
“Confirmed expectation of top line results in second half of 2026 from Phase 1b POC trials of ATI-052; announced Phase 2b program for ATI-052 starting in Q4 2026.”
“Expect to initiate Phase 1b proof-of-concept trials in AD and asthma shortly; planning underway for Phase 2b trial in AD in second half of 2026.”
Initiate a multi-part Phase 2b basket study of ATI-2138 in lichen planus subtypes starting in second half of 2026.
Stated as a priority in 3 of last 3 quarters. Management has consistently outlined plans to initiate a Phase 2b trial of ATI-2138 in lichen planus starting in the second half of 2026. The program remains on track with no reported delays, indicating delivery on this development milestone.
“Initiation of Phase 2b clinical program for modzatinib (ATI-2138) planned for Q4 2026 in lichen planus.”
“Announced lichen planus development strategy for ATI-2138; expect to initiate Part A of Phase 2b trial in second half of 2026.”
“Planning to initiate Phase 2b basket study of ATI-2138 in lichen planus in 2H 2026.”
Complete enrollment and report top line results from Phase 2 trial of bosakitug in atopic dermatitis in fourth quarter of 2026.
Stated as a priority in 2 of last 3 quarters. Enrollment in the Phase 2 bosakitug trial in AD is complete, with top line results expected in Q4 2026. Management has maintained this timeline consistently, indicating delivery on enrollment and progress toward data readout.
“On track for expected Q4 2026 readout of top line results from Phase 2 trial of bosakitug in AD; enrollment complete.”
“Completed enrollment in Phase 2 trial of bosakitug; confirmed expectation of top line results in Q4 2026.”
Ensure sufficient cash, cash equivalents, and marketable securities to fund operations through the end of 2028.
Over the trailing year it converted 1.10x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.